Peptide Manufacturer Supply Weight Loss Peptide CAS 2381089-83-2 Retatrutide Lyophilized Powder

What is retatrutide?

Retatrutide is a triple-action weight-loss injection manufactured by Eli Lilly. It’s undergoing later-stage human clinical trials to determine its effectiveness across a broader population. Retatrutide is known as a ‘triple hormone receptor agonist’. This means it mimics the actions of three hormones in the body that directly affect our ability to control hunger and our blood sugar levels. Retatrutide is likely going to be approved for individuals living with obesity and type 2 diabetes, should it receive approval from the MHRA in the UK and the FDA in the U.S. The three hormones that retatrutide mimics are: GLP-1: Lowers appetite and blood sugar levels GIP: Lowers appetite and blood sugar levels Glucagon: Promotes fat breakdown for energy use and prevents low blood sugar levels The triple action of retatrutide means it has a profound effect on appetite and the management of blood sugar levels and is expected to be more effective than semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) for weight loss.

What is the average weight loss on retatrutide?

In 2023, a randomised controlled trial on 338 participants showed that retatrutide supported an average weight loss of 24% after 48 weeks. If you weighed 100 kg, this would be a weight loss of 24kg. Additionally, 100% of participants on the higher doses of the drug lost more than 5% of their weight, 93% lost more than 10%, and 15% lost more than 15%. Strikingly, 26% of participants on the highest dose of retatrutide (12 mg) lost more than 30% of their body weight. Losing and maintaining weight loss of more than 10% is associated with significantly reducing complications related to obesity, including hypertension, type 2 diabetes, and heart disease. A recent paper published in The Lancet showed that nearly 20% of participants in lifestyle interventions without medications gain weight, around 40% lose between 1-10% of their body weight, and just 13% lose more than 10%. So, combining retatrutide with a lifestyle intervention leads to significantly greater weight loss than lifestyle interventions without medication.